Combined modality treatment in the management of high-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 5, 2004, Pages 1352-1359

  Stock, Richard G ^a   Cahlon, Oren ^a   Cesaretti, Jamie A ^a   Kollmeier, Marisa A ^a   Stone, Nelson N ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Combined modality; High risk; Locally advanced; Prostate cancer

Indexed keywords

BRACHYTHERAPY; HORMONAL THERAPY;

ANTIGENS; BIOCHEMISTRY; BIOPSY; DISEASE CONTROL; HEALTH RISKS; HORMONES; RADIOTHERAPY; TUMORS;

ONCOLOGY;

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CHEMICAL ANALYSIS; FOLLOW UP; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SCORING SYSTEM; SEMINAL VESICLE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; COMBINED MODALITY THERAPY; FINASTERIDE; FLUTAMIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY, CONFORMAL; TESTOSTERONE;

EID: 3242698141     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.01.023     Document Type: Article

References (46)

1. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974
2. Zietman A.L., Coen J.J., Shipley W.U., et al. Radical radiation therapy in the management of prostatic adenocarcinoma The initial prostate specific antigen value as a predictor of treatment outcome. J Urol. 15:1994;640-645
3. Shipley W.U., Thames H.D., Sandler H.M., et al. Radiation therapy for clinically localized prostate cancer A multi-institutional pooled analysis. JAMA. 281:1999;1598-1604
4. Kuban AK, El-Mahdi, Schellhammer PF. Prostate specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:307-316
5. Hanks G.E., Hanlon A.L., Hudes G., et al. Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy The need for improved systemic and locoregional treatment. J Clin Oncol. 14:1996;1093-1097
6. Kupelian P.A., Buchsbaum J.C., Elshaikh M., et al. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer. 95:2002;2302-2307
7. Hanks G.E., Lee W.R., Hanlon A.L., et al. Conformal technique dose escalation for prostate cancer Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥10 ng/mL. Int J Radiat Oncol Biol Phys. 35:1996;861-868
8. Gleave M.E., Goldenberg S.L., Chin J.L., et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy Biochemical and pathologic effects. J Urol. 166:2001;500-507
9. Pilepilch MV, Krall JM, Al-Sarrraf, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995;45:616-623
10. Petrovich Z., Lieskovsky G., Langholz B., et al. Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys. 53:2002;600-609
11. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response Results of the M. D. Anderson Phase III randomized trial. Int J Radiat Oncol Biol Phys. 53:2002;1097-1105
12. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500
13. Critz F.A., Tarlton R.S., Holladay D.A. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer I-125 implant followed by external-beam irradiation. Cancer. 75:1995;2382-2391
14. Dattoli M., Wallner K., Sorace R., et al. Pd-103 brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 35:1996;875-879
15. Lederman G.S., Cavanagh W., Albert P.S., et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys. 49:2001;1297-1303
16. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 166:2001;876-881
17. Martinez A., Gonzalez J., Spencer W., et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 169:2003;974-980
18. Stock RG, Stone NN, Kao J, et al. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy. Cancer 2000;89:1829-1834
19. Pollack A., Zagars G., Antolak J., et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure Analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys. 54:2002;677-685
20. Leibel S.A., Fuks Z., Zelefsky M.J., et al. The effects of local and regional treatment on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement. Int J Radiat Oncol Biol Phys. 28:1994;7-16
21. Fleming I.D., Cooper J.S. AJCC 1992 staging system. 1997;Lippincott- Raven, Philadelphia
22. Stock R.G., Stone N.N., Ianuzzi C., et al. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection Implications for patient selection in the radiotherapeutic management of prostate cancer. Int J Radiat Oncol Biol Phys. 33:1995;815-819
23. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 32:1995;219-225
24. 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Brachytherapy. 1:2002;2-10
25. Cox J.D., Grignon D.J., Kaplan R.S., et al. Consensus statement Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041
26. Norusis M.J. SPSS 10.0 guide to data analysis. 2000;Prentice-Hall, Upper Saddle River, NJ
27. Grossfeld G.D., Latini D.M., Lubeck D.P., et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 169:2003;157-163
28. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer A multi-institutional update. JAMA. 277:1997;1445-1451
29. Kuperlian A.L., Coen J.J., Levin H., et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urol. 48:1996;249-260
30. Zietman A.L., Edelstein R.A., Coen J.J., et al. Radical prostatectomy for adenocarcinoma of the prostate The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology. 43:1994;828-833
31. D'Amico A.V., Whittington R., Malkowicz S.B., et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 154:1995;131-138
32. Rosen M.A., Goldstone L., Lapin S., et al. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol. 148:1992;331-337
33. Jones E.C. Resection margin status in radical prostatectomy specimens Relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol. 152:1980;89-95
34. Trapasso J.G., deKernion J.B., Smith R.B., et al. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 152:1994;1821-1825
35. Potters L., Cha C., Ashley R., et al. The role of external beam irradiation in patients undergoing prostate brachytherapy. Urol Oncol. 5:2000;112-117
36. Hanks GE, Lu JD, Machtay M, et al. RTOG protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate [Abstract]. Int J Radiat Oncol Biol Phys 2000;48:112
37. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300
38. Pilepilch M.V., Kaplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy Report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol. 15:1997;1013-1021
39. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;247-252
40. Grossfeld G.D., Latini D.M., Lubeck D.P., et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 169:2003;157-163
41. Roach M. III, DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvis versus prostate only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression Radiation Therapy Oncology Group 9413. J Clin Oncol. 21:2003;1904-1911
42. Allepuz Losa C.A., Sanz Velez J.I., Gilsanz M.J., et al. Seminal vesicle biopsy in prostate cancer staging. J Urol. 154:1995;1407-1411
43. Terris M.K., McNeal J.E., Freiha F.S., et al. Efficacy of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J Urol. 149:1993;1035-1039
44. Vallencien G., Bochereau G., Wetzel O., et al. Influence of preoperative positive seminal vesicle biopsy on the staging of prostatic carcinoma. J Urol. 152:1994;1152-1156
45. Gleave M.E., Goldenberg L., Chin J.L., et al. Randomized comparative study of 3 vs. 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy 3 year PSA recurrence rates. [Abstract] J Urol. 169:2003;179
46. Hull G.W., Rabbani F., Abbas F., et al. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol. 167:2002;528-534